title: Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.
abstract: BACKGROUND
  New therapeutic modalities are needed for non-small cell lung cancer (NSCLC) patients whose tumors have become resistant to gefitinib.
  
  
  METHODS
  Between 2005 and 2008, 16 NSCLC patients, who had been previously treated with gefitinib and evaluated as partial response or complete response according to the response evaluation criteria in solid tumors (RECIST), received gefitinib plus paclitaxel. Paclitaxel was administered at 60 mg/m(2) on days 1, 8 and 15 every 4 weeks, and gefitinib was administered at 250 mg/day from the first day of administration of paclitaxel.
  
  
  RESULTS
  The response rate and disease control rate were 13% and 75%, respectively. The median progression-free survival (PFS) and median overall survival were 4.3 months and 8.1 months, respectively. The toxicities were mild, and there were no treatment-related deaths.
  
  
  CONCLUSIONS
  Gefitinib plus paclitaxel after failure of gefitinib exhibits activity and acceptable toxicity.
authors: Division of Thoracic Oncology, Shizuoka Cancer Center, Suntou-gun, Shizuoka 411-8777, Japan. tshukuya@juntendo.ac.jp
authors: Takehito
authors: T
authors: Shukuya
authors: Toshiaki
authors: T
authors: Takahashi
authors: Akihiro
authors: A
authors: Tamiya
authors: Akira
authors: A
authors: Ono
authors: Satoshi
authors: S
authors: Igawa
authors: Yukiko
authors: Y
authors: Nakamura
authors: Asuka
authors: A
authors: Tsuya
authors: Haruyasu
authors: H
authors: Murakami
authors: Tateaki
authors: T
authors: Naito
authors: Kyoichi
authors: K
authors: Kaira
authors: Masahiro
authors: M
authors: Endo
authors: Nobuyuki
authors: N
authors: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D016019:Survival Analysis
chemical_list: D011799:Quinazolines; D017239:Paclitaxel; D000077156:Gefitinib